EBS News and Press, Emergent Biosolutions Inc. From 10/09/20

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Eyes On Stimulus Developments AgainInvestors are still largely focused on new twists and turns with stimulus efforts in the U.S. Last night, President Dona...

Takeda (TAK) is among a group of companies who have begun testing an experimental COVID-19 treatment derived from convalescent plasma of those recovered from the disease. The study, funded by the National Institute of Allergy and Infectious Diseases, will compare the new drug in combination w...

Emergent BioSolutions (EBS) announces the initiation of an NIAID-sponsored Phase 3 clinical trial, INSIGHT-013, evaluating COVID-HIG (one of four such products), a hyperimmune immunoglobulin derived from plasma of people who have recovered from COVID-19, in hospitalized patients infected with...

NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19 Emergent is p...

Rushed to market just 6 months into the COVID-19 pandemic, the Pacer BioThreat Strategy ETF (VIRS) takes a unique approach to picking potential pandemic winners. The LifeSci BioThreat Strategy Index underlying VIRS selects holdings based on seven different criteria - everything from p...

Rushed to market just 6 months into the COVID-19 pandemic, the Pacer BioThreat Strategy ETF (VIRS) takes a unique approach to picking potential pandemic winners. The LifeSci BioThreat Strategy Index underlying VIRS selects holdings based on seven different criteria - everything from p...

Tiny Vaxart   (NASDAQ: VXRT) was just a penny stock back in January. Few people had heard of the company. You could buy a share for only 34 cents. And then COVID-19 hit, followed by stay-at-home orders, economic shut-downs, and the current recession. The public health crisis sent the enti...

Under normal circumstances, it would be considered highly unusual for a biotech or pharmaceutical company to start building out manufacturing capacity for a drug that hasn't yet been approved by the U.S. Food and Drug Administration (FDA). But 2020 has been anything but "normal." The United Stat...

GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it is teaming up with the Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and Mothers Against Prescription Drug Abuse (MAPDA) to highlight the importance of potentially l...

GAITHERSBURG, Md., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company’s board of directors appointed Marvin L. White as a Class II director to serve on the board effective October 1, 2020, with an initial term expiring at the 2023...